Relati onship between quality of life and BODE index of stable ex-smokers with chronic obstructive pulmonary disease

Česká verzia

Authors: V. Koblížek ¹; F. Salajka ¹; Eva Čermáková ² ; M. Tomšová ³; D. Pohnětalová ³; P. Papo ušek ⁴; V. Bartoš ¹; T. Dobešová ¹; Z. Paráková ¹; J. Ruta ¹; V. Sedlák ¹
Authors place of work: Plicní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MU Dr. František Salajka, CSc. ¹; Ústav lékařské biofyziky Lékařské fakulty UK Hradec Králové, přednosta doc. Ing. Josef Hanuš, CSc. ²; Fingerlandův ústav patologie Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MU Dr. Aleš Ryška, Ph. D. ³; Ústav patologické fyziologi e Lékařské fakulty UK Hradec Králové, přednosta prof. MU Dr. Miroslav Kuba, CSc. ⁴
Published in the journal: Vnitř Lék 2009; 55(10): 940-947
Category: Original Contributions

Summary

Background and aim:

This study was carried o ut to assess relationship between quality of life (QoL) and disease severity expressed by multifactorial prognostic index (BODE) in ex- smokers suffering from chronic obstructive pulmonary disease (COPD), minimally 8 weeks free of exacerbation. Materials and methods: The evaluati on was performed in 98 randomly recruited COPD patients enrolled into a cross- sectional, observational CILIARY study at the Department of Pneumology, Charles University, Faculty of Medicine in Hradec Králové. In them, quality of life evaluati on using the SGRQ questionnaire and the BODE index calculati on was performed. We statistically compared interrelationship between BODE and COPD stages, SGRQ and COPD stages and interrelation of BODE and SGRQ.

Results:
We found significant differences in QoL of COPD patients and QoL in group of he althy volunteers (p < 0.001). Lower QoL and higher BODE score were associated with a higher stages of COPD (p < 0.001), with the excepti on non‑significant difference in QoL (SGRQ score) and BODE index between stages I and II. Our study fo und positive correlati on between the all SGRQ scores and multidimensional prognostic BODE index (r = 0.431– 0.704). The strongest correlation (r = 0.704) was evident in activity domain of SGRQ.

Conclusion:
Our results proved close correlation of qu ality of life (SGRQ) and multidimensional prognostic score (BODE) in stable COPD exsmokers’ populati on. Both these scoring systems are useful tools for the assessment of clinical course and stratification of severity of COPD. However at present both scales are minimally used in the Czech Republic.

Key words:
chronic obstructive pulmonary disease (COPD) – St. George’s Respiratory Questionnaire (SGRQ) – Health-Related Quality of Life Questionanaire (HRQOL) – BODE index – forced expiratory volume in 1 s (FEV1) – body mass index (BMI) – Medical Research Council (MRC) dyspnea scale

Zdroje

1. ATS Statement. Guidelines for the six- minute walk test. Am J Respir Crit Care Med 2002; 166: 111– 117.

2. ATS/ ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166: 518– 624.

3. Antonelli- Incalzi R, Imperi ale C, Belli a V et al. Do GOLD stages of COPD severity really correspond to differences in health status. Eur Respir J 2003; 22: 444– 449.

4. Azarisman MS, Fauzi MA, Faizal MPA et al. The SAFE (SGRQ score, air– flow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad Med J 2007; 83: 492– 497.

5. Celli BR, Cote CG, Marin JM et al. The body‑mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005– 1012.

6. Chlumský J, Štěrbová L, Smolíková L et al. Vztah ventilačních plicních parametrů, tolerance fyzické zátěže a kvality života u pacientů s chronicko u obstrukční plicní nemocí. Vnitř Lék 2002; 48: 320– 324.

7. Claessens MT, Lynn J, Zhong Z et al. Dying with lung cancer or chronic obstructive disease: insights from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of Tre atments. J Am Geri atr Soc 2000; 48 (Suppl 5): S146– S153.

8. Chronic Obstructive Pulmonary Disease. Available from http:/ / www.who.int/ respiratory/ copd/ en.

9. Feenstra TL, van Genugten ML, Ho ogenveen RT el al. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164: 590– 596.

10. Fogli o K, Bi anchi L, Bruletti G et al. Seven- ye ar time course of lung functi on, symptoms, health‑related quality of life, and exercise tolerance in COPD patients undergo ing pulmonary rehabilitati on programs. Respir Med 2007; 101: 1961– 1970.

11. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Available from http://www.goldcopd.com.

12. Jemal A, Ward E, Hao Y et al. Trends in the leading cause of death in the United States, 1972– 2002. JAMA 2005; 294: 1255– 1259.

13. Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med 1991; 85 (Suppl B): 25– 31.

14. Kopecký O, Lukešová Š, Koblížek V et al. Pozdní komplikace chronických zánětů respiračního traktu u nemocných s běžno u variabilní imunodeficiencí. Vnitř Lék 2006; 52: 1021– 1029.

15. MacIntyre N, Crapo R, Viegi G et al. Standardisation of the single breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720– 735.

16. Miller MR, Crapo R, Hankinson J et al. General considerations for lung function testing. Eur Respir J 2005; 26: 153– 161.

17. Miller MR, Hankinson J, Brusasco V et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319– 338.

18. Murray CJ, Lopez AD. Regional patterns of disability – free life expectancy and disability – adjusted life expectancy: global Burden of Disease Study. Lancet 1997; 349: 1347– 1352.

19. Ong KC, Lu SJ, Soh CS. Does the multidimensional grading system (BODE) correspond to differences in he alth status of patients with COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 91– 96.

20. Pa uk N. Současné možnosti léčby CHOPN. Studia Pneumologica et Phtiseo-logica 2008; 5: 182– 190.

21. Salajka F. Hodnocení kvality života u nemocných s bronchiální obstrukcí. Praha: Grada 2006: 64– 65.

22. Salajka F. Proč hodnotit kvalitu života nemocných s bronchiální obstrukcí? Vnitř Lék 1999; 45: 480– 483.

23. Salajka F. Kvalita života nemocných s chronickou obstrukční plicní nemocí. Stud Pneumol Phtize ol 1997; 57: 137.

24. Salajka F. Kvalita života nemocných s bronchiální obstrukcí. Stud Pneumol Phtizeol 1997; 57: 262– 254.

25. Salajka F, Slováček K. Influence of baneotherapy and rehabilitation on quality of life in patients with bronchial obstruction. Chest 2003; 124 (Suppl 5): 105.

26. Santiveri C, Jones PW. Assessment of Symptoms and Duality of Life in the COPD Patient. In: Rennard SI, Ro isin RR, Huchon Get al (eds). Clinical Management of Chronic Obstructive Pulmonary Disease. Informa 2008; 89– 110.

27. Travers J, Laveneziana P, Webb KA et al. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. Respir Med 2007; 101: 2017– 2024.

28. de Torres JP, Cote CG, López MV et al. Sex differences in mortality in pati ents with COPD. Eur Respir J 2009; 33: 528– 535.

29. Wasserman K, Sue DY, Casaburi R et al. Selecti on criteria for exercise training in pulmonary rehabilitation. Eur Respir J Suppl 1989; 7: 604s– 610s.

30. Vondra V, Reisová M, Malý M. Metodologie zjišťování kvality života u nemocných s bronchiální obstrukcí. Stud Pneumol Phtiseol 2000; 60: 57– 62.

31. Vondra V, Reisová M, Malý M. Kvalita života u nemocných s bronchiální obstrukcí. Stud pneumol phtiseol 2000; 60: 73– 76.

32. Vondra V, Reisová M, Malý M. Kvalita života u nemocných s chronickou obstrukční plicní nemocí a bronchiálním astmatem. Čas Lék Čes 1998; 137: 455– 459.

33. Puhan MA, Garcia-Aymerich J, Frey M et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009, 374: 704–711.